Could your own immune cells beat brain cancer? new trial aims to find out
NCT ID NCT04943913
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early-phase study tests a treatment called GC101 TIL for people with brain glioma, a type of brain cancer. Doctors take immune cells from the patient's own tumor, grow them in a lab, and then put them back into the patient. The goal is to see if this approach is safe and can shrink tumors. The study involves about 50 adults who have not responded to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?
- Can a tiny implant trap brain tumor cells and make radiation work better?
- Can a targeted pill slow brain tumor growth after surgery?
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function